Undiagnosed Seroprevalence of Hepatitis B and C Virus Infections in the Community of Wolaita Zone, Southern Ethiopia.
Southern Ethiopia
Wolaita
hepatitis B virus
hepatitis C virus
seroprevalence
Journal
Hepatic medicine : evidence and research
ISSN: 1179-1535
Titre abrégé: Hepat Med
Pays: New Zealand
ID NLM: 101544801
Informations de publication
Date de publication:
2022
2022
Historique:
received:
09
05
2022
accepted:
29
07
2022
entrez:
16
8
2022
pubmed:
17
8
2022
medline:
17
8
2022
Statut:
epublish
Résumé
Despite Ethiopia's hepatitis endemic status with intermediate to hyperendemic level, there is no national strategy for monitoring, preventing, and controlling viral hepatitis. In order to advise community-based intervention programs, studies on the magnitude, determinant factors, and understanding of indigenous social organization are important. Thus, this study examined undiagnosed seroprevalence and associated factors for HBV and HCV infections among community members in Wolaita Zone, Southern Ethiopia. A cross-sectional study was conducted on 320 individuals from randomly selected two woredas in the Wolaita Zone to determine the magnitude of HBV and HCV. Multistage sampling was used to select participants. Relevant clinical and sociodemographic data were collected using a structured questionnaire. One test strip technique was used for the screening of hepatitis B surface antigen and for antibodies against HCV. Both tests were confirmed by ELISA methods. The associated factors were assessed using bivariate and multivariate logistic regression analyses. P-values less than 0.05 were considered statistically significant. The seroprevalence for HBV infection was 6.6% (95% CI: 4.22%, 8.69%) using a one-step HBsAg test strip and 5.6% (95% CI: 3.47%, 8.58%) using confirmatory test (ELISA). The two tests had a very good agreement (K = 0.918; SE = 0.047; P < 0.001). The overall seroprevalence for HCV infection was 1.9% (95% CI: 0.9%, 3.0%). All four of the one-step HCV test strip positives were also positive by ELISA. One (0.3%) of the participants was co-infected with HBV and HCV. Hospital admission (AOR = 0.22; 95% CI = 0.5-0.95) and needle stick (AOR = 0.15; 95% CI = 0.07-0.72) were independently associated with HBV infections. According to the current study, in Wolaita community, there is endemic to HBV at a higher-intermediate level and to HCV at a low level. It would be imperative to increase awareness of transmission modes and prevention of infection, as well as vaccination, in order to reduce the burden of both HBV and HCV.
Sections du résumé
Background
UNASSIGNED
Despite Ethiopia's hepatitis endemic status with intermediate to hyperendemic level, there is no national strategy for monitoring, preventing, and controlling viral hepatitis. In order to advise community-based intervention programs, studies on the magnitude, determinant factors, and understanding of indigenous social organization are important. Thus, this study examined undiagnosed seroprevalence and associated factors for HBV and HCV infections among community members in Wolaita Zone, Southern Ethiopia.
Methods
UNASSIGNED
A cross-sectional study was conducted on 320 individuals from randomly selected two woredas in the Wolaita Zone to determine the magnitude of HBV and HCV. Multistage sampling was used to select participants. Relevant clinical and sociodemographic data were collected using a structured questionnaire. One test strip technique was used for the screening of hepatitis B surface antigen and for antibodies against HCV. Both tests were confirmed by ELISA methods. The associated factors were assessed using bivariate and multivariate logistic regression analyses. P-values less than 0.05 were considered statistically significant.
Results
UNASSIGNED
The seroprevalence for HBV infection was 6.6% (95% CI: 4.22%, 8.69%) using a one-step HBsAg test strip and 5.6% (95% CI: 3.47%, 8.58%) using confirmatory test (ELISA). The two tests had a very good agreement (K = 0.918; SE = 0.047; P < 0.001). The overall seroprevalence for HCV infection was 1.9% (95% CI: 0.9%, 3.0%). All four of the one-step HCV test strip positives were also positive by ELISA. One (0.3%) of the participants was co-infected with HBV and HCV. Hospital admission (AOR = 0.22; 95% CI = 0.5-0.95) and needle stick (AOR = 0.15; 95% CI = 0.07-0.72) were independently associated with HBV infections.
Conclusion
UNASSIGNED
According to the current study, in Wolaita community, there is endemic to HBV at a higher-intermediate level and to HCV at a low level. It would be imperative to increase awareness of transmission modes and prevention of infection, as well as vaccination, in order to reduce the burden of both HBV and HCV.
Identifiants
pubmed: 35971532
doi: 10.2147/HMER.S374029
pii: 374029
pmc: PMC9375552
doi:
Types de publication
Journal Article
Langues
eng
Pagination
111-122Informations de copyright
© 2022 Kumalo et al.
Déclaration de conflit d'intérêts
None of the authors declared any conflicts of interest in this work.
Références
Lancet. 2015 Oct 17;386(10003):1546-55
pubmed: 26231459
Sci Rep. 2018 Jan 26;8(1):1661
pubmed: 29374178
J Clin Virol. 2012 Dec;55(4):296-302
pubmed: 22999800
R Soc Open Sci. 2018 Apr 11;5(4):180257
pubmed: 29765698
Hepatology. 2009 May;49(5 Suppl):S4-S12
pubmed: 19399804
Gastroenterology. 2012 May;142(6):1264-1273.e1
pubmed: 22537432
Ann Hematol. 2011 Feb;90(2):159-64
pubmed: 20821327
Cad Saude Publica. 2011 Apr;27(4):753-8
pubmed: 21603758
BMJ Open. 2017 Aug 28;7(8):e015748
pubmed: 28851778
BMC Public Health. 2013 Aug 07;13:727
pubmed: 23919752
BMC Infect Dis. 2013 Apr 18;13:181
pubmed: 23597411
Risk Manag Healthc Policy. 2021 Dec 01;14:4843-4852
pubmed: 34880693
BMC Infect Dis. 2016 Jun 13;16:283
pubmed: 27296465
Diabetes Care. 2004 Oct;27(10):2568-9; author reply 2569
pubmed: 15451946
BMC Public Health. 2017 Aug 4;17(1):636
pubmed: 28778194
Int J Gen Med. 2020 Jun 22;13:323-332
pubmed: 32606897
ScientificWorldJournal. 2021 Apr 09;2021:8873389
pubmed: 33897305
J Nat Sci Biol Med. 2016 Jan-Jun;7(1):72-4
pubmed: 27003974
Infect Dis Poverty. 2019 Mar 04;8(1):16
pubmed: 30827278
BMC Infect Dis. 2016 Dec 19;16(1):761
pubmed: 27993129
PLoS One. 2019 Dec 30;14(12):e0226890
pubmed: 31887192
Syst Rev. 2014 Dec 16;3:146
pubmed: 25516265
Clin Liver Dis. 2010 Feb;14(1):1-21, vii
pubmed: 20123436
Clin Microbiol Infect. 2011 Feb;17(2):107-15
pubmed: 21091831
PLoS One. 2020 Jun 17;15(6):e0234822
pubmed: 32555634
Hepatology. 2006 Jun;43(6):1303-10
pubmed: 16729298
World J Gastroenterol. 2018 Sep 14;24(34):3927-3957
pubmed: 30228786
Ann Med Health Sci Res. 2014 Sep;4(5):719-22
pubmed: 25328781
Hepat Mon. 2010 Summer;10(3):205-14
pubmed: 22308140
PLoS One. 2016 Feb 22;11(2):e0149966
pubmed: 26900839
BMC Res Notes. 2019 Jul 15;12(1):412
pubmed: 31307538
Vaccine. 2012 Mar 9;30(12):2212-9
pubmed: 22273662
AORN J. 2014 Jan;99(1):106-20
pubmed: 24369976
Virol J. 2011 Jan 12;8:12
pubmed: 21226907
MMWR Surveill Summ. 2008 Mar 21;57(2):1-24
pubmed: 18354374
Virol J. 2017 Feb 6;14(1):21
pubmed: 28166829
Hepatology. 2015 Jan;61(1):77-87
pubmed: 25069599
Dig Liver Dis. 2007 Jan;39(1):2-17
pubmed: 16884964
J Blood Med. 2020 Dec 31;11:543-550
pubmed: 33408547
BMC Infect Dis. 2016 Mar 01;16:101
pubmed: 26932656
BMC Public Health. 2020 May 19;20(1):721
pubmed: 32429964